This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The direct medical costs included drugs; contacts with the general practitioner, specialist, nurse, psychologist, and emergency services; hospital stay; laboratory tests; clinical examinations; and the treatment of adverse events. The resource quantities were from the HEADIS study, for health service use, and average patient-level data from IMS Heath, for antidepressant medications and adverse-event treatment. The unit costs were from the Dental and Pharmaceutical Benefits Agency, and the Southern Sweden Health Care Region price list. Productivity losses were based on the reported sick days in the HEADIS study. Items were valued in Swedish kronor, inflated to 2009 prices, and converted to Euros (EUR), at a rate of one kronor equalled EUR 0.096.
Analysis of uncertainty:
Ten thousand Monte Carlo simulations were run to produce means and 95% confidence intervals, using gamma and normal distributions for the model inputs. One-way sensitivity analyses were performed on the key parameters. A conservative scenario assumed that generic venlafaxine cost 5% of its branded price. The sensitivity analysis results were illustrated in a scatter plot and cost-effectiveness acceptability curves.
Results
The average total costs were EUR 7,378 (95% CI 1,518 to 21,630) for escitalopram, compared with EUR 7,547 (95% CI 1,571 to 21,371) for venlafaxine extended release; a difference of -EUR 169 (95% CI -1,632 to 1,070) per patient with escitalopram (cost saving).
The mean QALYs were 0.3151 (95% CI 0.2993 to 0.3302) for escitalopram and 0.3065 (95% CI 0.2903 to 0.3217) for venlafaxine; a gain of 0.009 QALYs (95% CI -0.002 to 0.020) with escitalopram.
The conservative scenario and the one-way sensitivity analyses showed that the findings were most sensitive to changes in the remission probability, and relatively insensitive to changes in the sick leave days, general practitioner visits, and incidence of nausea.
There was a 78.4% chance that escitalopram was cost-effective at a willingness-to-pay of EUR 22,080 per QALY gained (equivalent to £20,000 per QALY gained), compared with venlafaxine, and a 62.2% chance that escitalopram was dominant, being more effective and less costly.
